keyword
MENU ▼
Read by QxMD icon Read
search

HSDD

keyword
https://www.readbyqxmd.com/read/28499520/prevalence-and-predictors-of-low-sexual-desire-sexually-related-personal-distress-and-hypoactive-sexual-desire-dysfunction-in-a-community-based-sample-of-midlife-women
#1
Roisin Worsley, Robin J Bell, Pragya Gartoulla, Susan R Davis
BACKGROUND: Low desire is the most common sexual problem in women at midlife. Prevalence data are limited by lack of validated instruments or exclusion of un-partnered or sexually inactive women. AIM: To document the prevalence of and factors associated with low desire, sexually related personal distress, and hypoactive sexual desire dysfunction (HSDD) using validated instruments. METHODS: Cross-sectional, nationally representative, community-based sample of 2,020 Australian women 40 to 65 years old...
May 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28442935/new-developments-in-the-treatment-of-hypoactive-sexual-desire-disorder-a-focus-on-flibanserin
#2
REVIEW
Christopher J Jayne, Michael J Heard, Sarah Zubair, Dustie L Johnson
The objective of the authors is to highlight the historical complexities for the diagnosis and treatment of hypoactive sexual desire disorder (HSDD) with a focus on Flibanserin. A systematic review of the medical literature published in PubMed using the search terms HSDD and Flibanserin was conducted. Each author reviewed the results of the systematic review for articles to include in this study. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity causing marked distress or interpersonal difficulty that is not better accounted for by another diagnosis...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28434386/flibanserin-the-female-viagra
#3
Desiree Shapiro, Deanna Stevens, Stephen M Stahl
This article provides a clinically relevant review of the first medication approved by the US Food and Drug Administration for hypoactive sexual desire disorder (HSDD) in premenopausal women. In this short piece, the human sexual response cycle and its relevance to HSDD will be described as well as the pharmacological mechanism of action of flibanserin. Finally, efficacy and safety data of this new medication will be summarised.
April 24, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28397671/-flibanserin-as-pharmacological-therapy-of-inhibited-sexual-desire-in-women
#4
Anne Sofie Eldon, Annamaria Giraldi
Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD...
February 13, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28364864/evaluation-of-the-efficacy-and-safety-of-tribulus-terrestris-in-male-sexual-dysfunction-a-prospective-randomized-double-blind-placebo-controlled-clinical-trial
#5
Zdravko Kamenov, Svetlana Fileva, Krassimir Kalinov, Emmanuele A Jannini
OBJECTIVE: The primary objectives were to compare the efficacy of extracts of the plant Tribulus terrestris (TT; marketed as Tribestan), in comparison with placebo, for the treatment of men with erectile dysfunction (ED) and with or without hypoactive sexual desire disorder (HSDD), as well as to monitor the safety profile of the drug. The secondary objective was to evaluate the level of lipids in blood during treatment. PARTICIPANTS AND DESIGN: Phase IV, prospective, randomized, double-blind, placebo-controlled clinical trial in parallel groups...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28337949/efficacy-of-metacognitive-therapy-for-hypoactive-sexual-desire-disorder-among-iranian-couples
#6
Mohammad Arash Ramezani, Khodabakhsh Ahmadi, Mohammadali Besharat, Sima Noohi, Afagh Ghaemmaghami
OBJECTIVE: The aim of present study was to compare the efficacy of metacognitive therapy (MCT) against Masters-Johnson sex therapy (MJST) for hypoactive sexual desire disorder (HSDD) in Iranian couples. METHODS: A randomized treatment trial was conducted. Participants were recruited from the family counseling clinics in Tehran and Isfahan. All were suffering from HSDD as defined by DSM-IV-R criteria. They were assigned randomly to two groups that received 10 sessions of either MCT or MJST...
March 24, 2017: Psychotherapy Research: Journal of the Society for Psychotherapy Research
https://www.readbyqxmd.com/read/28203348/flibanserin-for-hypoactive-sexual-desire-disorder-place-in-therapy
#7
REVIEW
Faina Gelman, Jessica Atrio
The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access...
January 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28117267/androgens-and-psychosocial-factors-related-to-sexual-dysfunctions-in-premenopausal-women-%C3%A2-%C3%A2-2016-issm-female-sexual-dysfunction-prize
#8
Sarah Wåhlin-Jacobsen, Ellids Kristensen, Anette Tønnes Pedersen, Nanna Cassandra Laessøe, Arieh S Cohen, David M Hougaard, Marika Lundqvist, Annamaria Giraldi
INTRODUCTION: The female sexual response is complex and influenced by several biological, psychological, and social factors. Testosterone is believed to modulate a woman's sexual response and desire, because low levels are considered a risk factor for impaired sexual function, but previous studies have been inconclusive. AIM: To investigate how androgen levels and psychosocial factors are associated with female sexual dysfunction (FSD), including hypoactive sexual desire disorder (HSDD)...
March 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28113002/quantitative-and-qualitative-research-in-hsdd-the-difference-between-testing-theory-and-generating-new-theories
#9
Anita H Clayton, Robert E Pyke
Tiefer (2017) criticized our recent analysis of psychological treatment trials for HSDD (Pyke & Clayton, 2015) on what she claims to be scientific and "political" grounds. In the same letter, she alleged that we, and, by extension, the U.S. Food and Drug Administration, promoted drugs to the detriment of psychological treatment of female sexual problems. Such accusations require a serious response.
April 3, 2017: Journal of Sex & Marital Therapy
https://www.readbyqxmd.com/read/28079402/sexual-dysfunction-in-premenopausal-women-could-be-related-to-hormonal-profile
#10
Fabiene Bernardes Castro Vale, Bruna Barbosa Coimbra, Gerson Pereira Lopes, Selmo Geber
Female sexual dysfunction (FSD) is a public health problem that affects women's quality of life. Although the relationship between some hormones and the FSD has been described, it is not well established for all hormones. Therefore, the aim of our study was to evaluate the association between hormonal dysfunction and sexual dysfunction in premenopausal women. We performed a cross-sectional study with 60 patients with regular menstrual cycles, with age ranging from 18 to 44 years, with previous diagnosis of FSD...
February 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28050188/psychometric-properties-of-the-sexual-interest-and-desire-inventory-female-for-diagnosis-of-hypoactive-sexual-desire-disorder-the-persian-version
#11
Mina Malary, Mehdi Pourasghar, Soghra Khani, Mahmood Moosazadeh, Zeinab Hamzehgardeshi
Objective: Hypoactive sexual desire Disorder (HSDD) is a common sexual problem among women. Sexual interest and desire inventory -female (SIDI-F) has been widely validated and used to measure sexual desire in women. The aim of this study was to determine the psychometric properties of the Persian version of SIDI-F for Iranian population. Method: This was a methodological study on the psychometric properties of SIDI -F. This report describes the process and principles used in the translation and cultural adaptation of the SIDI-F on 40 women of reproductive age who were selected using convenience sampling method...
October 2016: Iranian Journal of Psychiatry
https://www.readbyqxmd.com/read/28041924/what-sexual-behaviors-relate-to-decreased-sexual-desire-in-women-a-review-and-proposal-for-end-points-in-treatment-trials-for-hypoactive-sexual-desire-disorder
#12
REVIEW
Robert Pyke, Anita Clayton
INTRODUCTION: Counts of satisfying sexual events (SSEs) per month have been criticized as an end point in treatment trials of women with hypoactive sexual desire disorder (HSDD) but grounding improvement in sexual desire by assessing changes in sexual behavior remains of some importance. METHODS: We conducted a literature review to find validated measurements that are specific sexual behavioral correlates of low sexual desire. We compared expert-proposed criteria for dysfunctional desire, expert-developed sets of scale items, and self-rated scales developed before issuance of, or in accordance with, the Food and Drug Administration's guidance on developing patient-reported outcomes...
December 29, 2016: Sexual Medicine
https://www.readbyqxmd.com/read/27916394/hypoactive-sexual-desire-disorder-international-society-for-the-study-of-women-s-sexual-health-isswsh-expert-consensus-panel-review
#13
REVIEW
Irwin Goldstein, Noel N Kim, Anita H Clayton, Leonard R DeRogatis, Annamaria Giraldi, Sharon J Parish, James Pfaus, James A Simon, Sheryl A Kingsberg, Cindy Meston, Stephen M Stahl, Kim Wallen, Roisin Worsley
The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels...
January 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27916205/efficacy-and-safety-of-transdermal-testosterone-in-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-systematic-review-and-meta-analysis
#14
Chiara Achilli, Jyotsna Pundir, Parimalam Ramanathan, Luca Sabatini, Haitham Hamoda, Nick Panay
OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). DESIGN: Systematic reviews and meta-analysis. SETTING: Not applicable. PATIENT(S): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo...
February 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/27872021/hypoactive-sexual-desire-disorder-a-review-of-epidemiology-biopsychology-diagnosis-and-treatment
#15
REVIEW
Sharon J Parish, Steven R Hahn
INTRODUCTION: Hypoactive Sexual Desire Disorder (HSDD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) as persistent deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), HSDD has been subsumed by Female Sexual Interest/Arousal Disorder. However, decades of research based on DSM-IV-TR HSDD criteria form the foundation of our understanding of the essential symptom of distressing low sexual desire, its epidemiology, clinical management, and treatment...
April 2016: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/27858170/flibanserin-and-its-discontents
#16
REVIEW
Awais Aftab, Cheryl Chen, Jacob McBride
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin's safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido...
November 17, 2016: Archives of Women's Mental Health
https://www.readbyqxmd.com/read/27824686/hypoactive-sexual-desire-dysfunction-in-community-dwelling-older-women
#17
Berihun M Zeleke, Robin J Bell, Baki Billah, Susan R Davis
OBJECTIVE: To determine the prevalence of hypoactive sexual desire dysfunction (HSDD) and its associated factors in women aged 65 to 79 years. METHODS: A questionnaire-based, cross-sectional study was conducted amongst community-dwelling older women. Participants were recruited between April and August 2014 from a national database based on electoral rolls. Sexual function and sexual distress were assessed by the Female Sexual Function Index and the Female Sexual Distress Scale-Revised, respectively...
November 7, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27823751/female-sexual-dysfunction-fsd-prevalence-and-impact-on-quality-of-life-qol
#18
REVIEW
Rossella E Nappi, Laura Cucinella, Silvia Martella, Margherita Rossi, Lara Tiranini, Ellis Martini
Female sexual dysfunction (FSD) and quality of life (QOL) are both multidimensional and have a bidirectional relationship across the reproductive life span and beyond. Methodological difficulties exist in estimating the real prevalence of FSD because it is hard to determine the level of distress associated with sexual symptoms in a large-scale survey. Approximately 40-50% of all women report at least one sexual symptom, and some conditions associated with hormonal changes at menopause, such as vulvovaginal atrophy (VVA) and hypoactive sexual desire disorder (HSDD), have a significant impact on sexual function and QOL...
December 2016: Maturitas
https://www.readbyqxmd.com/read/27784209/systematic-review-and-meta-analysis-of-flibanserin-s-effects-and-adverse-events-in-women-with-hypoactive-sexual-desire-disorder
#19
Amirhossein Sahebkar, Seyed Hassan Saadat, Yunes Panahi, Ali Kabir, Khaled Rahmani, Milad Hosseinialhashemi
The efficacy and safety of flibanserin in the treatment of Hypoactive Sexual Desire Disorder (HSDD) is controversial. We reviewed existing evidence on the efficacy and safety of flibanserin in treating HSDD, and performed a meta-analysis of reported effects. Literature search was performed on PubMed, Scopus, and Cochrane library to find all trials on the efficacy of flibanserin in HSDD. Meta-analysis was performed using fixed- and random-effects models. Egger's test and "trim and fill" methods were used for the assessment of publication bias and imputation of potentially missing studies, respectively...
October 25, 2016: Current Drug Metabolism
https://www.readbyqxmd.com/read/27663307/-efficacy-and-safety-of-flibanserin-new-female-viagra-%C3%A2-literature-review
#20
C Terrier, J-E Terrier
INTRODUCTION: In August 2015, the US Food and Drug Administration (FDA) has approved Addyi(®) (flibanserin) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre-menopausal women. We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. PATIENTS AND METHODS: A systematic literature review from the PubMed database search was carried out until April 2016 using the following keywords: "HSDD", "flibanserin", "sexual desire" and "ransomised controlled trial"...
September 2016: Progrès en Urologie
keyword
keyword
114579
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"